Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celsion Corp. (NASDAQ: CLSN).

Full DD Report for CLSN

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLSN)

Analysis: Positioning to Benefit within United Natural Foods, Capitol Federal Financial, Royal Gold, Celsion, National CineMedia, and Nu Skin Enterprises - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of United Natural Foods, Inc. (NASDAQ:UNFI), Capitol Federal Financial (NASDA...
Source: GlobeNewswire
Date: May, 15 2018 07:30
Celsion's (CLSN) CEO Michael Tardugno on Q1 2018 Results - Earnings Call Transcript
Celsion Corp. (CLSN) Q1 2018 Earnings Conference Call May 11, 2018 11:00 ET Executives Jeffrey Church - Senior Vice President and Chief Financial Officer Michael Tardugno - Chairman, President and Chief Executive Officer Nicholas Borys - Chief Medical Officer Analysts Emma ...
Source: SeekingAlpha
Date: May, 11 2018 17:09
Celsion net loss improves in Q1; shares ahead 14% premarket
Celsion ( CLSN ) Q1 results : Revenues: $0.1M (unch); Operating Loss: ($4.3M) (+10.4%); Net Loss: ($4.5M) (+13.5%); Loss Per Share: ($0.25) (+91.9%); Quick Assets: $2.3M (-79.8%). More news on: Celsion Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, ...
Source: SeekingAlpha
Date: May, 11 2018 08:32
Celsion reports Q1 results
Celsion (NASDAQ: CLSN ): Q1 EPS of -$0.25 More news on: Celsion Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 08:01
Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update
Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies  Supported with Solid Fundamentals and a Strong Balance Sheet                Company to Hold Conference Call on Friday, May 11, 2018 at 11:00 a.m. EDT ...
Source: GlobeNewswire
Date: May, 11 2018 08:00
Celsion Corporation to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
LAWRENCEVILLE, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Celsion Corporation to Hold First Quarter 2018 Financial Results Conference Call on Friday, May 11, 2018
LAWRENCEVILLE, N.J., May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its ...
Source: GlobeNewswire
Date: May, 04 2018 09:00
Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates
Stock Monitor: Celsion Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Egalet Corp. (NASDAQ: EGLT ). If you want access to this report all you need to do is sign up now by clicking the following link w...
Source: ACCESSWIRE IA
Date: April, 20 2018 07:00
International Liver Congress(TM) 2018 Symposium Highlights Celsion's ThermoDox® in Treatment of Primary Liver Cancer
   LAWRENCEVILLE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in Phase...
Source: GlobeNewswire
Date: April, 12 2018 08:00
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion's Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted Symposium, “Emerging Horizons in HCC: From Palliation to Cure,” on April 12, 2018 at Internat...
Source: GlobeNewswire
Date: April, 09 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-142.772.452.772.281,024,983
2018-08-132.702.74162.822.65150,885
2018-08-092.692.752.762.6994,456
2018-08-082.802.762.822.7577,769
2018-08-072.74362.792.802.740159,358

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1479,456264,91929.9926Cover
2018-08-134,18030,40513.7477Cover
2018-08-104,30236,29411.8532Cover
2018-08-098,22719,22742.7888Short
2018-08-0814,31526,58553.8462Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLSN.


About Celsion Corp. (NASDAQ: CLSN)

Logo for Celsion Corp. (NASDAQ: CLSN)

Not available

 

Contact Information

 

 

Current Management

  • Anthony P. Deasey / CFO, COO

Current Share Structure

  • Market Cap: $46,301,491 - 05/15/2018
  • Issue and Outstanding: 17,740,035 - 03/26/2018

 


Recent Filings from (NASDAQ: CLSN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018

 

 


Daily Technical Chart for (NASDAQ: CLSN)

Daily Technical Chart for (NASDAQ: CLSN)


Stay tuned for daily updates and more on (NASDAQ: CLSN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLSN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLSN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CLSN and does not buy, sell, or trade any shares of CLSN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/